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In recent decades, attention has focused
on reducing long-term, treatment-related
morbidity and mortality in Hodgkin lym-
phoma (HL). In the present study, we
looked for trends in relative survival for
all patients diagnosed with HL in Sweden
from 1973-2009 (N  6949; 3985 men and
2964 women; median age, 45 years) and
followed up for death until the end of
2010. Patients were categorized into 6 age
groups and 5 calendar periods (1973-
1979, 1980-1986, 1987-1994, 1994-2000,
and 2001-2009). Relative survival im-
proved in all age groups, with the great-
est improvement in patients 51-65 years
of age (P < .0005). A plateau in relative
survival was observed in patients below
65 years of age during the last calendar
period, suggesting a reduced long-term,
treatment-related mortality. The 10-year
relative survival for patients diagnosed in
2000-2009 was 0.95, 0.96, 0.93, 0.80, and
0.44 for the age groups 0-18, 19-35, 36-50,
51-65, and 66-80, respectively. Therefore,
despite progress, age at diagnosis re-
mains an important prognostic factor
(P < .0005). Advances in therapy for pa-
tients with limited and advanced-stage
HL have contributed to an increasing
cure rate. In addition, our findings sup-
port that long-term mortality of HL therapy
has decreased. Elderly HL patients still
do poorly, and targeted treatment options
associated with fewer side effects will
advance the clinical HL field. (Blood. 2012;
119(4):990-996)
Introduction
Over the past 40 years, major advances have been made in the
management of patients with Hodgkin lymphoma (HL). These
include the introduction of more accurate radiotherapy, effective
multiagent chemotherapy, immunotherapy, improved staging proce-
dures, and important developments in supportive measures for
myelosuppression and infectious and other complications.1 There-
fore, HL has gone from being an invariably fatal disorder to one of
the few malignancies that are now highly curable. This is particu-
larly true for patients with early-stage disease, but today disease
control rates also exceed 70% in patients presenting with high-risk
features.2 This therapeutic success has unfortunately been darkened
by elevated risks of secondary primary cancers, cardiovascular
disease (CVD), cerebrovascular disease, and infections in long-
term HL survivors.3-16
CVD has been reported to be the most important cause of excess
mortality after HL and second malignancies.10-11,13-14 During the
last 2-3 decades, treatment strategies have been and are being
adapted based on increased knowledge of treatment-related morbid-
ity and mortality. Awaiting novel and less toxic targeted therapies
of HL, the largest potential for improving survival and health-
related quality of life in long-term survivors17 is by reducing the
excess morbidity and mortality from causes other than HL. To
evaluate progress in long-term outcome, we studied patient sur-
vival among all 6949 HL patients diagnosed in Sweden between
1973 and 2009 and followed up for death to the end of 2010. Our
aim was to assess trends in patient survival and long-term excess
mortality in the entire population during this 37-year period
starting when curative treatment principles were well-established.
Methods
Central registers and patients
Information regarding patients diagnosed with a malignant disorder in
Sweden is reported to a population-based nationwide Swedish Cancer
Register that was established in 1958. The register contains information on
diagnosis, sex, date of birth, date of diagnosis, and the hospital where the
diagnosis was made,18-19 but does not contain detailed clinical information
such as symptoms, routine laboratory tests, treatment, or comorbidities.
In Sweden, every physician and pathologist/cytologist is obliged by law
to report each occurrence of cancer to the registry. All deaths are recorded in
the nationwide causes of death register. Each person in Sweden is given a
unique national registration number used to index all health registers used
in this study. We obtained aggregate-level information on the total number
of allogeneic and autologous stem cell transplantations (SCTs) performed in
HL patients in Sweden during the study period from the European Group
for Blood and Marrow Transplantation (EBMT) register, which was
established in 1974. The Swedish Cancer Registry classifies all cases using
International Classification of Diseases Version 7 (ICD-7). We identified all
patients diagnosed with HL (ICD-7 201) between January 1, 1973 and
December 31, 2009 in the Swedish Cancer Register. For the 16 individuals
registered as having multiple primary HL, we only considered the first
diagnosis. We did not otherwise exclude patients on the basis of previous
cancer diagnoses. HL patients diagnosed incidentally at autopsy or whose
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diagnosis was not verified microscopically were excluded from the
analyses. In a re-evaluation of 251 tumor biopsies from patients 15 years
of age diagnosed with HL in Sweden from 1985-1994, the diagnosis of HL
was confirmed in 89% of the tumors.20
All patients were followed from the date of diagnosis until death,
emigration, or end of follow-up (December 31, 2010), whichever occurred
first. The choice to include patients from 1973 was because, by then, the
Swedish Cancer Register had reached a high coverage18,21 and because
treatment with MOPP (mechlorethamine, vincristine, procarbazine, and
prednisone) had been introduced as standard induction treatment for most
patients with advanced disease judged eligible for aggressive treatment.22-23
The study was approved by the Stockholm Ethics Review Board.
Treatment principles of HL during the study period
During the entire study period (1973-2009), treatment principles for HL in
Sweden have followed those of the international Western medical commu-
nity. In the beginning of this period, most patients with limited disease
(stages I-IIA, sometimes stages IIB/IIIA) received radiotherapy (mantle/
para-aortic/inverted Y field/total nodal irradiation). After the report by
de Vita et al,22 MOPP chemotherapy was introduced for patients with
advanced disease (stages IIIB-IV). The Stockholm Hodgkin Lymphoma
Study Group was established in 197323 and national Swedish treatment
recommendations for HL were introduced in 1985 and have been updated
over the years.24-26 In 1975, the successful use of the combination ABVD
(doxorubicin, bleomycin, vinblastine, dacarbazine) was reported,27 and
since the early 1980s, a variety of chemotherapy combinations other than
conventional MOPP, including ABVD, MOPP/ABVD, MOPP/ABV (for
younger patients), and ChLVPP (chlorambucil, vinblastine, procarbazine,
prednisolone), LVPP/OEPA (chlorambucil, vinblastine, procarbazine, vin-
cristine, etoposide, prednisone, doxorubicin), and CHOP (cyclophosph-
amide, doxorubicin, vincristine, prednisone; mostly elderly patients) were
used in previously untreated patients with stage IIB-IV disease.28-32 Since
the 1980s patients with advanced disease reaching a complete remission
after 2 cycles traditionally received a total of 6 cycles of chemotherapy.29,33
Very few HL patients with advanced disease and high-risk features received
BEACOPP chemotherapy (bleomycin, etoposide, doxorubicin, cyclophos-
phamide, vincristine, procarbazine, prednisone) during the study period.2,34
Combined modality treatment for patients with limited-stage disease
became increasingly common during the 1980s.35 Irradiation for previously
bulky disease in patients with stage III-IV disease was also widespread
during the 1980s and 1990s. High-dose chemotherapy with autologous
SCTs for patients with refractory/relapsing disease was started in the
mid-1980s with BEAM (carmustine, etoposide, cytarabine, melphalan) as
the prevailing high-dose regimen.36-37 Staging during the period 1972-1988
often included laparotomy and splenectomy.38-39 The management of frail
elderly patients has been more varied.32,40-41 During recent years, treatment
of HL has been increasingly influenced by the goal of minimizing late
therapy-related complications. Therefore, a more tailored treatment has
become an important concept to offer the best chance of cure with reduced
risk of toxicity. As an example, a common Nordic protocol for patients with
stage I-IIA disease based on risk-adjusted treatment was initiated in 1999.42
Survival analysis
Relative survival ratios (RSRs) were computed as measures of HL
survival.43-44 An important advantage of using relative survival is that it
does not rely on the accurate classification of cause of death. Instead, it
provides a measure of total excess mortality associated with a diagnosis of
HL irrespective of whether the excess mortality is directly or indirectly
because of the cancer. As such, the RSR captures excess mortality because
of, for example, treatment-related CVD or secondary malignancies, which
is not possible when using cause-specific survival. The RSR is defined as
the observed survival in the patient group (where all deaths are considered
as events) divided by the expected survival of a comparable group from the
general population free from the cancer in question. One-year, 5-year, and
10-year RSRs can be interpreted as the proportion of HL patients who
survive 1, 5, and 10 years, respectively, in the hypothetical scenario where
HL is the only possible cause of death. Expected survival was estimated
using the Ederer II method45 from Swedish population life tables stratified
by age, sex, and calendar period. RSRs were calculated for patients
diagnosed during 5 calendar periods, 1973-1979, 1980-1986, 1987-1994,
1994-2000, and 2001-2009, and 6 age categories, 0-18, 19-35, 36-50,
51-65, 66-80, and 80 years. Poisson regression was used to model excess
mortality46 to estimate the effects of the factors described above while
controlling for potential confounding factors. The parameter estimates from
this model are interpreted as excess mortality ratios; an excess mortality
ratio of 1.5, for example, for males/females indicates that males experience
50% higher excess mortality (the difference between observed and expected
mortality) than females. All calculations were performed using Stata
Version 11.2 software (StataCorp).
Results
A total of 6949 HL patients, 3985 men (57%) and 2964 women
(43%) with a median age of 45 years (range, 2-99 years) were
included in the study (Table 1). The male predominance was more
marked in early calendar periods, but persisted throughout the
study period (Table 1 and supplemental Figure 1, available on the
Table 1. Characteristics of patients diagnosed with HL in Sweden from 1973 to 2009
1973-1979 1980-1986 1987-1993 1994-2000 2001-2009 Total
Sex, n (%)
Male 1006 (61) 729 (57) 702 (57) 684 (57) 864 (55) 3985 (57)
Female 643 (39) 558 (43) 534 (43) 512 (43) 717 (45) 2964 (43)
Total 1649 1287 1236 1196 1581 6949
Age at diagnosis, y, n (%)
0-18 92 (5.6) 98 (7.6) 146 (11.8) 146 (12.2) 172 (10.9) 654 (9.4)
19-35 362 (21.9) 338 (26.3) 374 (30.3) 441 (36.9) 557 (35.2) 2072 (29.8)
36-50 243 (14.7) 224 (17.4) 220 (17.8) 183 (15.3) 253 (16.0) 1123 (16.2)
51-65 389 (23.6) 230 (17.9) 189 (15.3) 173 (14.5) 272 (17.2) 1253 (18.0)
66-80 463 (28.1) 318 (24.7) 248 (20.1) 199 (16.6) 246 (15.6) 1474 (21.2)
81 or older 100 (6.1) 79 (6.1) 59 (4.8) 54 (4.5) 81 (5.1) 373 (5.4)
Median age, y 57 49 41 36 39 45
SCTs, n
Allogeneic NI 0* 0† 1 37 38
Autologous NI 2* 49† 96 163 310
NI indicates no information available.
*No information was available for 1980-1985.
†No information was available for 1987.
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Blood Web site; see the Supplemental Materials link at the top of
the online article). The age-standardized overall incidence rate
decreased until the early to mid-1990s and then remained essen-
tially stable (supplemental Figure 1). The decline in incidence is
driven primarily by the pattern among males 50 years of age or
older, and there is evidence of a slight increase in incidence
among children and younger adults ( 34 years; supplemental
Figures 2 and 3).
Figure 1. Relative survival of HL patients in Sweden diagnosed from 1973-2009. Estimates of 1-year (A), 5-year (B), and 10-year (C) relative survival among HL patients
stratified by age category and calendar period of diagnosis.
Figure 2. Cumulative relative survival among HL patients in Sweden stratified by age at diagnosis and calendar period of diagnosis.
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A total of 348 SCTs in HL, 38 allogeneic and 310 autologous,
were reported to the EBMT registry during the study period. Of
these, more than half (57%) were carried out during the last
calendar period, with autologous SCT dominating (Table 1).
There was significant improvement in 1-, 5-, and 10-year RSR
across the study period in all age groups (Figure 1A-C), although
the most pronounced improvements in 5- and 10-year RSR were
seen among patients 36-50, 51-65, and 66-80 years of age,
respectively, and was most conspicuous among patients 51-65 years
of age (Figure 1B-C). This is also illustrated in Figures 2 and
3, which show the cumulative relative survival stratified by age at
diagnosis and calendar period. During the last calendar period,
there seems to be a plateau in relative survival after 5 years in
patients up to 65 years of age. A plateau in the cumulative relative
survival curve indicates that the patients experience the same
mortality as the general population—that is, that there is no
evidence of HL-related excess mortality.
Excess mortality rates during the first 10 years after diagnosis
were significantly lower in later calendar periods (P  .0005) and
in younger patients (P  .0005; Table 2). Females had a 19% lower
excess mortality compared with males during the first 10 years after
diagnosis (P  .0005; Table 2).
Discussion
Based on the analysis of this large nationwide cohort of 6949 HL
patients, there has been a significant gradual improvement in
prognosis over the last 3 decades. The better outcome was observed
in 1-, 5-, and 10-year relative survival, and was most conspicuous
in patients 36-80 years of age at diagnosis. However, 5- and
10-year relative survival improved significantly in all age catego-
ries except in the very old ( 80 years). Although the age-related
differences in survival are decreasing, age at diagnosis remains a
strong predictor of prognosis.30,40,47 A recent analysis of the
Surveillance, Epidemiology, and End Results (SEER) database of
the United States National Cancer Institute showed a particular
improvement in 10-year relative survival of HL patients
45-59 years of age and those 60 years of age and older.48 This is
consistent with our findings, although we also observed improve-
ments in patients 65-80 years of age at diagnosis.
In the 4 youngest age categories (up to 65 years) a plateau in relative
survival was observed after 5 years during the last calendar period,
indicating that patients surviving 5 years experience the same mortality
as the general population and suggesting that long-term treatment
mortality has decreased drastically. In the SEER-based study, relative
survival did not reach a clear plateau for any age group.48 Even though
long-term follow-up information was not available for the majority of
our patients in the last calendar period, we believe that these findings are
important. The results reflect an improved tumor control, but also
confirm that the goal to reduce late therapy–related fatal complications
has been successful. Therefore, a more tailored treatment has become an
Figure 3. Cumulative relative survival among HL patients in Sweden stratified by calendar period of diagnosis and age at diagnosis. Data for 1980-1986 are not
shown.
Table 2. Excess mortality rate ratios and 95% CIs during the first
10 years after HL diagnosis by calendar period, sex, region, and
age at diagnosis
Excess mortality rate ratio 95% CI
Calendar period of HL diagnosis (P < .0005)
1973-1979 1.00 (reference)
1980-1986 0.67 (0.59-0.74)
1987-1994 0.49 (0.43-0.55)
1995-2000 0.32 (0.28-0.38)
2001-2009 0.28 (0.24-0.33)
Sex (P < .0005)
Male 1.00 (reference)
Female 0.81 (0.74-0.88)
Health-care region of diagnosis (P  .18)
Stockholm/Gotland 0.92 (0.82-1.04)
Other 1.00 (reference)
Age at HL diagnosis, y (P < .0005)
0-18 1.00 (reference)
19-35 1.36 (1.01-1.83)
36-50 2.41 (1.79-3.24)
51-65 6.13 (4.63-8.12)
65-80 13.10 (9.94-17.28)
 80 25.17 (20.13-36.66)
All variables are simultaneously adjusted for all other variables in the table.
P values are provided for the likelihood ratio test comparing the model without the
specific factor with the model with all factors.
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important concept to offer the best chance of cure with reduced risk of
toxicity, particularly in younger patients. The introduction of combined
modality treatment in patients with localized disease, which has allowed
reduced irradiation fields and abbreviated chemotherapy35 and ABVD
chemotherapy for advanced disease,28 has probably contributed the
most to this improvement. However, even if the results of the present
study favor the concept that lower doses of radiation will reduce the risk
of late fatal toxicities, we still lack long-term detailed follow-up data.49
Moreover, high-dose chemotherapy with autologous SCT for patients
with refractory/relapsing disease was an important addition to the
therapeutic armamentarium.36
During the study period of 1973-2009, the incidence of HL
decreased significantly in people more than 40 years of age, and
this pattern was more pronounced in men. This is also reflected in a
decreasing median age of patients in our study. Although the
reasons for this decline are obscure, Hjalgrim et al noticed a
significantly decreased incidence of non-nodular sclerosis subtypes
and unspecified HL in the age group of 40 years and above during
1978-1997, and suggested that changes in diagnostic procedures
may have contributed to the observed decline.50 Concomitantly,
there was a smaller slow but significant increase in incidence
among adolescents and young adults, which was reported to occur
primarily for HL of the nodular sclerosis subtype.50 In good
agreement with previous observations, the age-adjusted HL inci-
dence was higher in men51 and we also found a significantly better
survival for women when adjusted for age and calendar period.30
In the present study, when calculating RSR estimates, we
compared survival among all Swedish HL patients with the total
Swedish population as a reference group. In contrast, Brenner
et al used SEER data for patients diagnosed from 1973-2004
covering a population of about 30 million people and compared HL
survival with that of the total United States population.48 Another
difference between our study and the study by Brenner et al is that
they used a period analysis, whereas in the present study, we used a
cohort approach.48 Cohort estimates represent the actual survival
experience of a well-defined cohort of patients, which is not the
case for period estimates. Although not directly comparable
because of minor differences in age categories and calendar period,
relative survival appears overall to be somewhat better in the
Swedish population during the latest calendar period under study
for patients up to 45 years of age at diagnosis. This was also
confirmed when, to facilitate a direct comparison, we estimated
5-year relative survival using a period approach (period window
2000-2004) with the same age categories as Brenner et al.48 The
estimated 5-year relative survival ratios (with the estimates from
Table 2 in Brenner et al48 given in parentheses) were: 15-24 years,
0.95 (0.94); 25-34 years, 0.98 (0.93); 35-44 years, 0.97 (0.89);
45-59 years, 0.86 (0.83); and 60 years and over, 0.59 (0.59). Even if
survival of patients aged 60 is the same in the 2 countries, we
believe that the proportion of very elderly is higher in Sweden. For
readers interested in predictions of survival for recently diagnosed
patients, we present results from a period analysis using the most
up-to-date available data (period window 2007-2010) in supplemen-
tal Figure 4. There are several potential explanations for the higher
survival in Sweden. First, an important difference between the
2 studies relates to the inherent differences in the medical health-
care systems between the United States and Sweden. Sweden has a
well-established government-funded public health-care system in
which all residents by law are entitled to equal access to health
services. Second, patients with HL are almost exclusively diag-
nosed, treated, and followed clinically by physicians at nonprivate,
hospital-based hematology/oncology units. As a consequence,
treatment decisions, including autologous (and allogeneic) SCTs,
are based solely on patient- and disease-related factors independent
of financial considerations. Third, in the mid-1980s, national
Swedish guidelines for the diagnosis and treatment of HL were
introduced and updated on a regular basis. Notwithstanding the
better outcome of Swedish patients, an impressive improvement in
relative survival over time has clearly been documented in both
studies. It is possible that some of the improvements in survival can
be explained by changes in disease characteristics (with a more a
favorable distribution of prognostic factors in recent years).
Detailed information on clinical prognostic factors is not available
on a national level for the entire study period, but we obtained data
from 2 clinical registers spanning the study period to identify
potential changes in disease characteristics. We obtained informa-
tion from the Stockholm HL group for patients diagnosed in the
Stockholm area from 1973-1994 and from the Swedish National
Lymphoma Register for all patients diagnosed in Sweden from
2000-2008. We saw no evidence that the distribution of stage or
presence of B-cell symptoms changed during the course of the
study (supplemental Table 1). There was evidence that the propor-
tion of patients with nodular sclerosing subtype has increased over
time, but the trends in subtype are difficult to interpret because of
changes in how subtype is classified and improvements in diagnos-
tics (supplemental Table 2).
In the present study, we used a register-based cohort design that
ensured a population-based setting and generalization of our
findings. We computed RSR estimates as measures of HL survival,
which is in contrast to reports on survival from clinical trials. A
major advantage of using RSR as the measure of survival is that
information on cause of death is not required and the measure
captures excess mortality both directly and indirectly because of
HL (eg, treatment-related mortality). The crucial assumption in
working with RSR estimates is that one can accurately estimate
expected survival. For most cancers (including HL), patients are
representative of the general population of the same age and sex, so
their expected survival can be estimated using general-population
survival rates and subsequent estimates of relative survival can be
interpreted as a measures of excess mortality because of the
cancer.44 In contrast to reports based on patients treated in clinical
trials, the large majority of patients in this study ( 95%) were
treated in routine clinical practice. Therefore, elderly patients and
patients not treated with curative intent were included in the
analysis. This study therefore supplies a more complete picture of
the survival of HL patients in the population.
Limitations of the present study include lack of clinical data for
individual patients and detailed changes in diagnostic practices/
accuracy over time. Conversely, it is not likely that the observed
improved survival is influenced by an increased access to health-
care and earlier detection of the disease over time (ie, lead-time
bias). Most probably, a combination of factors related to diagnos-
tics, staging, and treatment have contributed to the observed
improvements in HL survival. In parallel to specific HL treatment
strategies that have developed over time, important developments
in supportive measures for myelosuppression, infections, and other
complications have been introduced. Despite this progress, survival
remains substantially lower in elderly patients, especially those
above 80 years of age. Many elderly patients are not fit for
intensive chemotherapy or radiotherapy because of comorbidities
and poor performance status, leading to low complete remission
rates and inferior survival.
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In summary, in the present study, we found that HL patients
younger than 80 years have gained significantly from the develop-
ments in management of the disease during a 37-year period.
However, age still remains an important predictor of prognosis,
which is why innovative agents and procedures suitable for the
older patient are needed. More individualized management based
on accurate risk stratification will hopefully further improve the
outlook for the whole HL patient population. In addition, continued
analysis of late effects associated with newer treatment for HL will
be imperative for today’s and tomorrow’s patients.
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